Drug Trial Radar · NCT03874013
Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency
Last checked: Nov 20, 2026Latest source record: Aug 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Dec 7, 2017
Primary completion
Mar 6, 2020
Study completion Mar 6, 2020
Sponsor
- Lead sponsor
- OPKO Health, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Treatment of children with growth failure due to growth hormone deficiency (GHD). Primary • To evaluate the efficacy and safety of weekly MOD-4023 administration compared to daily Genotropin® administration in Japanese pre-pubertal children with GHD. Secondary • To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of three different doses of MOD-4023 in Japanese pre-pubertal children with GHD.
Conditions
- Growth Hormone Deficiency
Interventions
MOD-4023Drug
MOD-4023 is a long-acting modified recombinant human growth hormone (r-hGH) which utilizes C-terminal peptide (CTP) technology. It will be provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a multi-dose disposable pre-filled PEN. MOD-4023 will be administered as a SC injection once weekly, using a delivery device.
GenotropinDrug
Genotropin® is dispensed in a 2-chamber cartridge. The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. The rear compartment contains m-Cresol and mannitol in water for injections. A delivery device (Genotropin®) will be used for daily (evening/bedtime) SC administration of Genotropin® into the region of the upper arms, buttocks, thighs or abdomen (8 locations). Injection sites should be rotated. Dose regimen for Genotropin®: 0.025 mg/kg/day (or 0.175 mg/kg/w divided equally to 7 injections over a week).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual Height Velocity (HV) After 12 MonthsTime frame: 12 months
Locations
46 sites in 1 country. Site status is shown where the registry gives one.
Akita University Hospital
Akita, Japan
Fukuoka Children's Hospital
Fukuoka, Japan
Gifu University Hospital
Gifu, Japan
Hiroshima City Hospital Organization Hiroshima City Hiroshima Citizens Hospital
Hiroshima, Japan
Kumamoto University Hospital
Kumamoto, Japan
Miyazaki Prefectural Miyazaki Hospital
Miyazaki, Japan
Arakawa Children's Clinic
Nagano, Japan
Nara Prefecture General Medical Center
Nara, Japan
Niigata University Medical & Dental Hospital
Niigata, Japan
Okayama Saiseikai General Hospital Outpatient Center
Okayama, Japan
National Hospital Organization Okayama Medical Center
Okayama, Japan
Osaka City General Hospital
Osaka, Japan
Osaka City University Hospital
Osaka, Japan
Saitama Childrens Medical Center
Saitama, Japan
Saitama City Hospital
Saitama, Japan
Shizuoka Childrens Hospital
Shizuoka, Japan
Toranomon Hospital
Tokyo, Japan
Aichi Medical University Hospital
Nagakute, Aichi-ken, Japan
Seirei Sakura Citizen Hospital
Sakura, Chiba, Japan
Hospital of the University of Occupational and Environmental Health
Kitakyushu, Fukuoka, Japan
Gunma University Hospital
Maebashi, Gunma, Japan
Fukuyama City Hospital
Fukuyama, Hiroshima, Japan
National Hospital Organization Kure Medical Center & Chugoku Cancer Center
Kure, Hiroshima, Japan
Onomichi General Hospital
Onomichi, Hiroshima, Japan
Hokkaido P.W.F.A.C. Asahikawa-Kosei General Hospital
Asahikawa, Hokkaido, Japan
Asahikawa Medical University Hospital
Asahikawa, Hokkaido, Japan
KKR Sapporo Medical Center
Sapporo, Hokkaido, Japan
Kobe University Hospital
Kobe, Hyōgo, Japan
Takahashi Clinic
Kobe, Hyōgo, Japan
Takarazuka City Hospital
Takarazuka, Hyōgo, Japan
St. Marianna University School of Medicine Hospital
Kawasaki, Kanagawa, Japan
National Hospital Organization Minami Kyoto Hospital
Jōyō, Kyoto, Japan
East Japan Railway Company Sendai Branch Office JR Sendai Hospital
Sendai, Miyagi, Japan
National University Corporation Tohoku University Tohoku University Hospital
Sendai, Miyagi, Japan
Igarashi childrens clinic
Sendai, Miyagi, Japan
Oita University Hospital
Yufu, Oita Prefecture, Japan
Osaka Women's and Children's Hospital
Izumi, Osaka, Japan
Osaka University Hospital
Suita, Osaka, Japan
Saitama Medical University Hospital
Iruma-Gun, Saitama, Japan
Saitama Medical Center
Kawagoe, Saitama, Japan
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.